MA-VERISTAT
22.10.2020 10:15:06 CEST | Business Wire | Press release
Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.
Veristat , a scientific minded clinical research organization, announced today the launch of their Global Cell and Gene Therapy Center of Excellence (COE). The COE comprises a multi-disciplinary team of scientific experts who are adept at strategy and execution across this complex clinical development pathway. Veristat’s experience supporting these unique programs in the Americas and Europe enables them to implement impactful advisory and tactical services to support the challenging decisions required to advance a cell and gene therapy to market. Leveraging the learnings from the support of numerous client cell and gene therapy programs, including the first gene therapy approved in Europe, the Global COE will serve as a powerhouse for sponsors and as a mechanism to share insights, successful strategies, and best practices.
“We understand how high the stakes are with cell and gene therapy programs,” stated Alecia Barbee, Executive Vice President, Operations at Veristat, “and that nothing is standard about the therapies, the studies or the regulatory processes in this specialized area. Veristat has successfully supported more than 100 cell and gene therapy projects across the entire clinical development life-cycle, and with the launch of our center of excellence, we are formalizing our processes to assist sponsors around the globe to bring these advanced therapies to market quickly.”
Every cell or gene therapy is unique, often coming with a complicated regulatory approval process and unique therapeutic challenges. Even the best therapeutic may not reach patients who need it if the study design and execution are not optimal. Veristat offers tailored solutions across the entire clinical development pathway to combat these challenges, including:
- The ability to develop your therapeutic with accelerated approval pathways and/or special designations
- A review of operational aspects of the protocol and feedback on any potential obstacles/challenges that could impact the protocol execution at the clinical research sites
- Novel strategies including implementation of a centralized site model and remote monitoring with direct-to-patient capabilities
- Expertise in logistics and handling of live cellular material
- Development of bespoke regulatory strategies for the type of cell and gene therapy and the unmet clinical need acceptable to the regulatory agencies
- Long-term follow-up strategies to meet global regulatory requirements
“The challenges of developing cell and gene therapies requires a committed and experienced partner,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Cell and gene therapies offer uniquely curative potential for disorders that are intractable to other treatment modalities. They can save lives. The challenge now is to scale the opportunity they offer to their full potential. Our years of experience in this specialized area and reputation for success will make Veristat the CRO of choice for small and medium biopharmaceutical companies who want to bring their cell or gene therapies to patients worldwide.”
About Veristat:
Veristat , a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005181/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Instabase Becomes SuperApp, Launches the AI Collaboration Super App17.8.2026 12:00:00 CEST | Press release
AI was single-player. SuperApp makes it multiplayer Your whole team and leading AI models from Anthropic, OpenAI, Google, xAI, and others think, debate, and create together in one live thread — from the first idea to the final deliverable. Available today. SuperApp, Inc., formerly Instabase, Inc., today launched SuperApp, the AI collaboration super app, available on the web, iOS, Android, and desktop. SuperApp brings teams and leading AI models from Anthropic, OpenAI, Google, xAI, and others into one live thread — from the first conversation to finished work. The company changed its name to reflect the new product and company direction. Work today is split into three. Teams talk in one app. They ask AI in another. They make the final work somewhere else. Every handoff asks people to remember what the software forgot. SuperApp brings those moments together. People and AI begin in the same live thread. Teams can use Claude from Anthropic, GPT from OpenAI, Gemini from Google, Grok from xA
Confluence Launches Confluence POINT, Bringing AI-Enabled Automation Across Its Product Suite.17.8.2026 11:04:00 CEST | Press release
Document validation and intelligence and the Revolution conversational interface are live today; the first in a wave of AI capabilities running within and alongside Confluence’s solutions. Confluence Technologies, Inc. (“Confluence”), a global leader in regulatory, analytics, and investor communications solutions for the investment management industry, today announced the launch of Confluence POINT, AI-enabled automation that optimizes workflows across its solutions. Confluence delivers specialist regulatory, analytics and investor solutions that are unrivalled at what they do. POINT is AI-enabled automation that runs within and alongside these solutions, letting them do more for our clients, reducing manual effort that typically occurs before or after automated processes. POINT Validation transforms and validates documents across a range of formats, including unstructured data. POINT’s AI-powered validation is complete in minutes, delivered via an automated checklist that runs indepen
Xsolla Adds 15+ New Local Payment Methods, Letting Game Developers Reach Players Across Asia-Pacific, Europe, and the Americas17.8.2026 10:00:00 CEST | Press release
Now Live: Mandiri, ShopeePay, LINE Pay, Octopus, Konbini 7/11, China UnionPay, Zip Co, Wero, Pay by Bank, FLOA Pay BNPL, Bancomat Pay, MyBank, IRIS Commerce, CliQ, and Aeropay Xsolla, a global video game commerce company, today announced the addition of 15+ new payment methods to Xsolla Payments ahead of Gamescom 2026, spanning Asia and Oceania, EMEA, and the Americas. Game developers and publishers can now accept the local payment methods players already use, across markets from Indonesia and the Philippines to Germany, France, and the United States, with no additional integration required for any individual method. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817000143/en/ Graphic: Xsolla The shift toward local payment methods is reshaping the digital payments landscape well beyond emerging markets. Across Europe, banks and regulators are building account-to-account and instant-payment alternatives to international ca
SES Expands into Global Direct-to-Device Services through Strategic Collaboration with Elveo Mobile17.8.2026 09:30:00 CEST | Press release
SES, a global leader in space solutions, today announced an expanded strategic investment and collaboration with Elveo Mobile (Elveo), the new company created through the completion of the Lynk and Omnispace merger. Elveo unites the heritage of two pioneers in direct-to-device (D2D) services and will deliver mobile connectivity from space to mobile phones, devices and machines around the world. SES will support Elveo in accelerating its delivery of powerful, cost-effective global D2D services. SES and Elveo will also work together on global spectrum initiatives that will enable Elveo to unlock delivery of D2D solutions. By partnering with Elveo, SES deepens its commitment with access to its expansive, global space and ground infrastructure, while also supporting Elveo's go-to-market, engineering, operations and regulatory needs. The collaboration will enable SES to enhance current services for its mobile telecom, enterprise, and government customers around the world. SES users will ben
Trading Central Launches a UCITS ETF17.8.2026 09:30:00 CEST | Press release
Trading Central SA (“Trading Central”) announces the launch of a UCITS European Quant ETF in partnership with HANetf Asset Management, one of Europe’s leading white-label UCITS ETF and ETC platforms. The following ETF is now trading on Euronext Paris (eligible to PEA), Milan, Dublin, and Börse Frankfurt, and is coming soon to more European stock exchanges and in currencies besides the Euro. Trading Central Quant Europe 50 Equity UCITS ETF (TCQE) J.P. Morgan serves as fund administrator and custodian, while GTX acts as the market maker across these exchanges. This release marks Trading Central’s continued expansion into investable products, supporting self-directed retail clients with its award-winning, proprietary financial research and data. “For years, Trading Central has helped investors make more informed decisions through independent research and analytics,” said Alain Pellier, CEO of Trading Central SA. “The introduction of our TC Quant ETF is a natural next step in our mission—o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
